Matthew manages the coalition’s multilateral policy analysis and advocacy work. He develops and implements outreach strategies to the various United Nations agencies and other multilateral organizations to ensure that the coalition is advocating a consistent position with all global health R&D stakeholders.
Matthew has a background in global health diplomacy. Prior to joining GHTC he served for four years in the Multilateral Diplomacy section of the Office of the US Global AIDS Coordinator at the US Department of State. As the Advisor for Multilateral Diplomacy, he led policy analysis and development, as well as assisting in outreach and negotiation efforts on a number of key Global Fund issues, with primary responsibility for those arising in the Policy and Strategy Committee. He has held positions with the Global Fund to Fight AIDS, TB and Malaria, as well as UNICEF, in addition to interning with the Population Council and the Woodrow Wilson International Center for Scholars.
Matthew received his MA in Global Human Development (with a specialization in global health systems) from Georgetown University School of Foreign Service, and his BA in Philosophy (with a concentration in systems of logical analysis) from Bates College. For a number of years he held a full racing license and in his free time still enjoys long drives on winding country roads.
The 140th session of the World Health Organization (WHO) Executive Board (EB) closed last week with a shortlist of three candidates for the WHO Director General position and progress on key global health R&D issues.
We asked. WHO listened. The World Health Organization (WHO) took the first step toward establishing an essential diagnostics list, releasing a proposal outling how it plans to develop and operationalize the list by early 2019.
With the 140th World Health Organization Executive Board meeting commencing this week, GHTC takes a look at what's on the agenda and how it could impact global health R&D.
An essential diagnostic list list in a smart, cost-effective idea that could advance diagnostic R&D and access.
At the United Nations General Assembly, world leaders made an unprecedented collective commitment to fighting the growing problem of antimicrobial resistance. GHTC and Global Health Council analyze what that commitment entails, why it matters, and the importance of what happens next.
As happens every May, the World Health Organization’s (WHO) highest governing body, the World Health Assembly (WHA), met last week for its 69th annual meeting in Geneva, Switzerland. The agenda was the most packed in recent memory, consisting of more than 70 discussion items, many of which were controversial. Despite the lengthy agenda and difficult conversations, the WHA made two key decisions impacting global health research and development (R&D).
This coming week the “who’s who” of the global health community (as well as some much more modest global health advocates such as your humble author) will make the annual trek to Geneva, Switzerland, for the 69th World Health Assembly (WHA), where World Health Organization (WHO) member states will collectively decide WHO’s plans for the coming year.
Last week, GHTC convened a panel of experts to dissect and discuss a proposal for pooled funding for global health research and development (R&D).
With the New Year underway, GHTC is looking forward to a busy spring of multilateral organization meetings—with a number of them impacting global health research and development (R&D). First on the agenda is the World Health Organization (WHO) Executive Board (EB) meeting on January 25–30 in Geneva, where the EB will receive updates on a number of topics and make important decisions, particularly around how to proceed with the next steps of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) process.